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Synergistic effects of conjugated linoleic acid and chromium
picolinate improve vascular function and renal pathophysiology
in the insulin-resistant JCR:LA-cp rat
S. D. Proctor,1 S. E. Kelly,1 K. L. Stanhope,2 P. J. Havel2 and J. C. Russell1
1Metabolic and Cardiovascular Diseases Laboratory, Alberta Institute for Human Nutrition, 4–10 Agriculture Forestry Centre,
University of Alberta, Edmonton, AB, Canada
2Department of Nutrition, University of California, Davis, CA, USA
Aims: Conjugated linoleic acid (CLA) is a natural constituent of dairy products, specific isomers of which have
recently been found to have insulin sensitizing and possible antiobesity actions. Chromium is a micronutrient which,
as the picolinate (CrP), has been shown to increase insulin sensitivity in animal models, including the JCR:LA-cp rat.
We tested the hypothesis that these agents may have beneficial synergistic effects on the micro- and
macrovasculopathy associated with hyperinsulinaemia and early type 2 diabetes.
Methods: Insulin-resistant cp/cp rats of the JCR:LA-cp strain were treated with mixed isomers of CLA (1.5% w/w in
the chow) and/or CrP at 80 mg/kg/day (expressed as Cr) from 4 weeks of age to 12 weeks of age. Plasma insulin, lipid
and adiponectin levels, aortic vascular function, renal function and glomerular sclerosis were assessed.
Results: CLA administration reduced food intake, body weight and fasting insulin in JCR:LA-cp rats. Plasma
adiponectin levels were significantly elevated in rats treated with both CLA and CrP. Aortic hypercontractility was
reduced and the relaxant response to the nitric oxide-releasing agent acetylcholine (Ach) was increased in CrP-treated
rats. Striking reductions were also observed in the level of urinary albumin and the severity of glomerular sclerosis in
rats treated specifically with CLA.
Conclusions: CLA and CrP have beneficial effects ameliorating several of the pathophysiologic features of an insulin-
resistant rat model. These supplements may be useful adjuncts in the management of patients with the metabolic
syndrome and warrant further study.
Keywords: adiponectin, chromium, conjugated linoleic acid, glomerular sclerosis, insulin resistance, JCR:LA-cp rat, metabolic syn-
drome, prediabetes, vasculopathy
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Introduction
The metabolic syndrome, characterized by abdominal
obesity, insulin resistance, dyslipidaemia and endothe-
lial/vascular dysfunction, is a prediabetic state [1,2]. The
chronic sequelae of the metabolic syndrome are macro-
and microvascular (particularly renal vascular) diseases
[3]. Recently, there has been a renewed focus on the
capacity of bio-active dietary components to reduce the
metabolic and pathological complications of type 2 dia-
betes, particularly in the early prediabetic phase.
Conjugated linoleic acid (CLA) is a collective term for
a group of conjugated dienoic isomers of linoleic acid
(18:2, o-6), formed by bacterial transformation of
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linoleic acid [4]. The cis-9, trans-11 isomer is the
common component found in dairy products, whereas
trans-10, cis-12 is a product of synthetic alkaline iso-
merization of linoleic acid found in commercial CLA
supplements. CLA has been shown to improve glucose
tolerance and insulin resistance in rodent models and
humans, possibly via a thiazolidinedione-like action
[5–7]. There is some evidence that CLA may protect
against atherogenesis [8], possibly by increasing ago-
nist-mediated nitric oxide (NO) release and reducing
levels of inflammatory mediators within vascular
endothelial cells [9]. Ogborn et al. [10] showed that
glomerular haemostatic regulation, including ecosanoid
and prostaglandin activity, can be improved by supple-
mentation with CLA. The expression and secretion of
adipokines have also been implicated in the regulation
of glomerular filtration rate as well as endocrine effects
on insulin sensitivity [11–13].
By contrast, chromium is a transition metal element
that, like others in the same elemental series, has poten-
tial metabolic effects and is classified as a micronutrient
with accepted minimum daily intake [14]. Crþþþ, as
chromium picolinate (CrP), has been shown to increase
insulin sensitivity in animal models of insulin resistance,
including the JCR:LA-cp rat [15]. There is also evidence
of insulin-sensitizing action of chromium in cultured
muscle cells possibly due to modulation of intracellular
tyrosine kinase activity and Ca2þ concentrations [16]. CrP
has been shown not to produce any measurable toxic
effects in rats or mice, suggesting that it may be an effec-
tive therapeutic option [17]. We proposed that selective
combination of both CLA and CrP treatment represents a
unique therapeutic and synergistic approach to the pre-
vention of chronic complications of type 2 diabetes. To
investigate this hypothesis, we used an established rat
model of the metabolic syndrome, hyperinsulinaemia
and cardiovascular disease, the JCR:LA-cp rat.
The JCR:LA-cp rat is a unique strain that exhibits
marked obesity and hyperinsulinaemia, resulting from
a defect in the leptin receptor gene [18], with associated
micro- and macrovascular disease [19,20]. This strain
mimics the pathophysiology of the obese prediabetic
human and has become a model-of-choice for study of
prediabetes and complications of the metabolic syn-
drome [19–28]. Reduction of insulin concentrations in
the cp/cp rat is associated with corresponding reduction
in vasculopathy and cardiac dysfunction and can pre-
vent ischaemic lesions of the heart [24–28]. Evidence
from this study suggests that co-supplementation with
CLA and CrP results in synergistic and striking func-
tional improvements in the macro- and microvascular
system of the cp/cp rat.
Materials and Methods
Animals and Treatment
Male rats of the JCR:LA-cp strain, obese (cp/cp) and
lean [þ/?, a 2:1 mix of heterozygous (cp/þ) and homo-
zygous normal (þ/þ)], were raised and housed as
described previously [20,21]. The strain has recently
been rederived and established at Charles River
Laboratories (Wilmington, MA, USA) with the designa-
tion Crl:JCR(LA)-Leprcp. From 4 weeks of age, cp/cp
animals were provided food containing (i) mixed iso-
mers of CLA (Tonalin, Cogniz Corp. USA, Cincinnati,
OH, USA) at a concentration of 1.5% (w/w); (ii) CrP at a
concentration to deliver a dose of 80 mg/kg/day
(expressed as elemental Cr); or (iii) both additives.
Groups not receiving CLA, including controls, received
1.5% canola oil in the food as a lipid balance control.
Food was formulated with Lab Diet 5001 (PMI Nutrition
International, Brentwood, MO, USA) [27]. Rats were
treated to 13 weeks of age, with a meal tolerance test
performed 1 week prior to killing.
All animals were weighed and their food consump-
tion measured twice weekly in order to maintain the
desired dose of CrP on a mg/kg body weight basis. Rats
were killed in the fed state under halothane anaesthesia
by exsanguination from the heart, and collection of
blood and urine samples. Care of animals and experi-
mental procedures were in conformity with the guide-
lines of the Canadian Council on Animal Care and
subject to prior review and approval by the Heath
Sciences Animal Policy and Welfare Committee of the
University of Alberta.
Meal Tolerance Test
Insulin sensitivity was assessed at 12 weeks of age
through a meal tolerance test developed in our labora-
tory [21,28]. Tests were performed following a standard-
ized, conscious, non-restraint protocol, a challenge of
5 g of rat chow and blood samples taken fasting
(0 time) and 30 and 60 min after consumption of the meal.
Vascular Function
Vascular function of aortic rings with intact endo-
thelium was determined as previously described
[28,29]. Contractile concentration–response curves for
phenylephrine (PE) (0.1 nmol/l to 100 mmol/l, Sigma
Chemicals, Oakville, Ontario, Canada) were determined.
NO-mediated relaxation of aortic rings (precontracted
with PE to 80% of maximal contraction) was determined
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using the endothelial NO-releasing agent, acetylcholine
(ACh) (Sigma Chemicals), and the NO donor sodium
nitroprusside (SNP) (Sigma Chemicals). Direct assess-
ment of NO-mediated effects was also determined
through addition of NG-nitro-L-arginine methyl ester
(L-NAME) (Sigma Chemicals), at 104 mol/l, in order to
inhibit NO synthase (NOS) activity [29].
Analytical Methods
Plasma glucose was measured using a rapid glucose oxi-
dase technique (Beckman Instruments, Brea, CA, USA),
and insulin was assayed by a double antibody radio-
immunoassay technique (Kabi Pharmacia, Uppsala,
Sweden). Adiponectin was measured by radio-immuno-
assay (LINCO Research, St Louis, MO, USA). The plasma
lipid profile was measured using the gas chromato-
graphic technique of Kuksis et al. [30]. Urine albumin
and creatinine concentrations were measured using
immuno-turbidimetric and Jaffe´ methods, respectively.
Renal Histology
Kidneys were divided along the long axis, fixed, sec-
tioned and stained with H&E. Sections were examined
to quantify glomerular sclerosis by the method of Scha¨fer
et al. [31]. Ten random fields of view of each kidney were
recorded digitally using a 10 objective. All complete
glomeruli in each field of view were scored, blinded, as
sclerotic (mild to severe glomerular sclerosis) or normal
(minimal sclerosis or normal). The fraction of sclerotic
glomeruli was calculated for each kidney.
Statistical Analysis
Results are expressed as mean – s.e.m. Data were
plotted using SIGMAPLOT (SPSS, Chicago, IL, USA) and
PRISM (Graphpad, San Diego, CA, USA) and analysed
using one-way analysis of variance (ANOVA) followed by
multiple comparison tests (SigmaStat, Jandel Scientific,
San Rafael, CA, USA). Concentration–response curves
were analysed using the program ALLFIT [32], which fits
the entire data set to the logistic equation and permits
independent testing of differences between individual
parameters.
Results
Food Intake and Body Weight
The body weight curves of cp/cp and þ/? rats differ
from an early age (figure 1). During the initial 2 weeks
of the treatment period (4 and 6 weeks of age), there was
no detectable difference in food intake or body weight
between the CLA-treated (alone or with CrP) cp/cp rats
and the þ/? controls. By 6 weeks of age, when these
animals rapidly develop the phenotype of hyperinsulin-
aemia and the metabolic syndrome, the food intake and
body weight of the CLA-treated rats diverged from the
þ/? controls towards values for the cp/cp control ani-
mals. At 12 weeks of age, food intake was not signifi-
cantly reduced in CLA-treated rats (30.0 – 1.7 vs.
34.1 – 1.4 g/day, p ¼ 0.0906) and was greater than that
of the þ/? controls (22.5 – 0.4 g/day). Similarly the
body weights, at 12.5 weeks of age, were reduced in
CLA-treated cp/cp rats (412 – 8 vs. 476 – 12 g), but
still greater than þ/? animals (323 – 6 g). In contrast to
CLA, CrP administered alone or in combination had no
effect on food intake or body weight.
Insulin Sensitivity
The cp/cp rats supplemented with CLA (with or without
CrP) had significantly lower fasting insulin levels com-
pared with untreated cp/cp rats (p < 0.002) (figure 2).
Following the meal challenge, animals supplemented
with combination therapy (CLA þ CrP) showed a reduc-
tion in the insulin response at 30 min (p < 0.002) that
was not evident with either agent alone. There was no
difference between the fasting plasma concentrations of
glucose (or at the 30-min time point) for the four groups
of cp/cp rats (data not shown).
Biochemical Parameters
All lipid classes are moderately to markedly elevated in
cp/cp compared with þ/? animals (figure 3). The CrP-
treated rats had a significant decrease in non-esterified
cholesterol, but not in esterified cholesterol or other
lipids. CLA-treated rats (with or without CrP) showed
significant reduction in cholesterol ester levels
(p < 0.01 and p < 0.005). Rats supplemented with
both CLA and CrP demonstrated reduction in trigly-
ceride and phospholipid fractions (37 and 19%, respec-
tively, p < 0.05).
Plasma adiponectin concentrations did not differ
between untreated cp/cp animals and those supplemen-
ted with either CLA or CrP alone (5.22 – 0.57,
6.00 – 0.41 and 5.17 – 0.52 mg/ml, respectively).
However, plasma adiponectin concentrations increased
by approximately 54% (8.02 – 0.42 mg/ml, p < 0.01) in
rats treated with both CLA and CrP.
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Fig. 1 Food intake and body weight of
JCR:LA-cp rats. Values are mean – s.e.m.,
10 rats in each group. Significant differ-
ences between groups are discussed in
the text.
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Fig. 2 Plasma insulin concentrations
of JCR:LA-cp rats, fasted (0 min)
and 30 and 60 min following a 5-g meal
challenge. Values are mean – s.e.m.,
8–10 rats in each group. **p < 0.01,
***p < 0.001 vs. cp/cp control.
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Vascular Function Studies
Contractile response of aortae from þ/? rats was lower
than that of aortae from cp/cp rats (figure 4). The maxi-
mum contractile response of aortae from CrP-treated rats
was significantly lower (p < 0.02). Furthermore, there
was a significant decrease in the EC50 for ACh-mediated
relaxation of aortae from CrP-treated rats. By contrast,
there was no difference in the contractile response to
PE, or relaxant response to ACh, of aortae from rats
treated with CLA (with or without CrP). There was no
difference in the contractile response to PE in the
presence of L-NAME between any of the groups nor
any difference in the relaxant response to SNP (data
not shown).
Renal Effects
Urinary albumin concentrations are elevated in cp/cp
animals at 12 weeks of age (figure 5). The data showed
a greater variance when expressed as the albumin/
creatinine ratio, and albumin data only are shown.
Supplementation with CLA (either alone or combined
Li
pi
d 
co
nc
en
tra
tio
n 
(m
m)
0.0
0.5
1.0
1.5
2.0
2.5 +/? control
cp/cp control
cp/cp CrP
cp/cp CLA
cp/cp CLA + CrP
Free
Chol
Chol
Esters
Total
Chol
Phospho-
Lipid
Triglyceride
*
***
**
*
*
Fig. 3 Plasma lipid concentrations of
13-week-old JCR:LA-cp rats. Values are
mean – s.e.m., 8–10 rats in each group.
*p < 0.05, **p < 0.01, ***p < 0.001
vs. cp/cp control.
–9 –8 –7 –6 –5 –4
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5 Without L-NAME
cp/cp control
CrP
+/? control
CLA
CrP + CLA
Log (PE) m
Fo
rc
e 
(g)
–9 –8 –7 –6 –5 –4
With L-NAME
Log (PE) m
–9 –8 –7 –6 –5 –4
25
50
75
100
R
el
ax
at
io
n 
(%
)
Log (ACh) m
Fig. 4 Contractile/relaxation function of aortic rings from JCR:LA-cp rats: dose response to PE in the absence (left panel) and
presence (middle panel) of the NOS inhibitor L-NAME (104 mol/l; relaxant dose response to ACh (right panel). Values are
mean – s.e.m., 8–10 rats in each group. The maximum contractile response of þ/? aortae was lower than that of cp/cp aortae
(1.47 – 0.202 and 2.15 – 0.128 g, respectively, p < 0.01). The maximum contractile response of aortae of CrP-treated rats was
lower (1.78 – 0.062 g, p < 0.02). There was no difference in the contractile response of aortae from rats treated with CLA
(either with or without CrP. EC50 for ACh-mediated relaxation of aortae from CrP-treated rats was decreased (1.84 – 0.42 
106 to 5.6 – 1.07  107 M, p < 0.0001). The aortae of rats treated with CLA (with or without CrP) showed no change in
the relaxant response to ACh compared with untreated cp/cp rats.
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with CrP) resulted in significant reduction in urinary
albumin levels (75 and 85%, respectively, p < 0.05).
Treatment with CrP alone resulted in an approximately
50% decrease in albumin levels (statistically insignifi-
cant due to the high variance in the control group).
The cp/cp rat exhibits a greater severity of glomerulo-
sclerosis than the þ/? rat, despite the early age of
12 weeks (figure 5). There was a striking and distinctive
reduction in the fraction of sclerotic glomeruli of CrP-
treated rats (p < 0.0001) and even further in CLA-
treated rats (p < 0.0001). Rats treated with the combina-
tion of both CLA and CrP showed an intermediate but
also highly significant reduction (p < 0.0001).
Discussion
The progression of the metabolic syndrome is accompa-
nied by vascular dysfunction and culminates in type 2
diabetes, ischaemic coronary disease and/or end-stage
renal injury. The process is complex and not well
understood. We report here, for the first time, that diet-
ary supplementation with CLA and CrP, in combina-
tion, can contribute significantly to the reduction of
vascular dysfunction and renal sequelae in an
established animal model of the metabolic syndrome
and prediabetic state.
Food Intake and Weight Gain
CLA – administered from 4 weeks of age, i.e. before the
onset of the development of insulin resistance in the cp/
cp rat [19] – temporarily normalized food intake and the
rate of weight gain. However, the effect waned rapidly
after 6 weeks of age. Regression analysis of the body
weight data at the end of the treatment period, between
9.5 and 12 weeks of age, revealed that the rate of weight
gain of the CLA-treated rats was equivalent to that of the
cp/cp control rats (4.11 – 0.44 and 5.06 – 0.74 g/day,
respectively, p ¼ 0.294) with þ/? rats having a much
lower rate (1.73 – 0.36 g/day, p ¼ 0.002 vs. cp/cp).
These results suggest that CLA may be most beneficial
when administered at an early age, prior to the develop-
ment of frank obesity and insulin resistance. By con-
trast, CrP appeared to exert its beneficial metabolic
effects when obesity and insulin resistance were fully
established.
Metabolism of Glucose and Insulin
Insulin resistance in the cp/cp rat is evident in the
fasting hyperinsulinaemia with euglycaemia [21]. The
meal tolerance test provides a well-documented physio-
logical index of insulin sensitivity through both fasting
and postprandial insulin levels [21,25–28]. Treatment
with CLA reduced fasting plasma insulin concentra-
tions, which is consistent with improved insulin sensi-
tivity found in many other CLA-related studies. It
appears that many of these endocrine/adipogenic effects
are modulated by CLA’s ability to stimulate the prolif-
erator-activated receptor (PPAR) pathway in the adipo-
cyte [33]. By contrast, CrP, which had no effect on body
weight gain, did not reduce fasting insulin levels,
despite the relatively high pharmacological dose given
in this study. It is possible that the potential mechan-
ism(s) of action of CrP (thought to be elicited through
chromodulin) may be masked by the extreme hyperin-
sulinaemia in these animals. However, the combination
group that received both CLA and CrP were the only
animals to show a significantly reduced insulin
response 30 min after the meal challenge, suggesting a
synergistic effect. The absence of changes in plasma
glucose levels for any of the treatment groups is consis-
tent with the observation that the cp/cp rat maintains
relative normoglycaemia, albeit at the expense of very
high circulating insulin concentrations [21].
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Lipid Metabolism
When CrP and CLA were supplemented individually,
the unesterified or esterified fractions of cholesterol
were modestly reduced, respectively, supportive of dif-
ferential mechanisms of lipid modulation. It has been
suggested that CLA reduces both the production and
secretion of apoB100 (an obligatory marker for VLDL
assembly) by human hepatocytes [34]. Decreased intra-
cellular concentrations of cholesterol esters are thought
to facilitate a greater rate of intracellular proteolytic
degradation of apoB100 (consistent with observations
from this study). Other studies have shown that CLA
can increase LDL receptor protein and mRNA
expression in HepG2 cells, furthering the potential cho-
lesterol-lowering effects of CLA [35]. By contrast, the
mechanism(s) of action for CrP are less well understood.
Previous studies have been based on the hypothesis that
beneficial effects of CrP on lipid/cholesterol levels are
an indirect and secondary consequence of its insulin-
sensitizing properties [15]. Recent reports have pro-
vided evidence of a functional role for chromodulin, a
small oligopeptide that can tightly bind up to four Crþþþ
ions [36]. Chromodulin is thought to activate tyrosine
kinase activity of the insulin receptor and may explain
(at least in part) the independent insulin-sensitizing
actions of CrP observed in this study. Collectively,
these distinct independent mechanisms of action, for
both CLA and CrP, are indicative of synergistic bio-
activity, particularly with respect to insulin sensitiza-
tion and lipid lowering.
Adiponectin
Adiponectin is secreted by adipocytes and considered
to be a marker of inflammation with lower plasma con-
centrations in both obese humans and rodent models of
obesity/insulin resistance [37–39]. While adiponectin
levels in obese cp/cp rats supplemented with either
CLA or CrP alone were not significantly different from
those in untreated cp/cp animals, adiponectin was
increased by approximately 54% by the combination of
the two supplements. This suggests a reduction in
inflammation and is consistent with the reduced glo-
merular sclerosis seen in the treated rats. Nagao and
colleagues [12,40] have reported that CLA increased
mRNA expression for adiponectin in adipose tissue
from fa/fa ZDF rats, consistent with activation of the
PPAR pathway. It is also possible that CrP-associated
chromodulin has intracellular stabilizing effects on the
typrosine-kinase pathway that may add to the appar-
ently enhanced secretion of adiponectin observed.
Adiponectin is known to circulate in multimeric aggre-
gates of different molecular weight [41]. Treatment with
thiazolidendione agonists of PPARg, which have insu-
lin-sensitizing effects in the cp/cp rat [27], increases the
ratio of the higher molecular weight to the lower weight
forms and can be predictive of improved insulin sensi-
tivity [41].
Vascular Function
Improvements in vascular function were limited to ves-
sels from animals treated with CrP alone. The observed
reduction in maximum contractile response to PE is
physiologically significant and suggests a direct role
for CrP in modulation of vascular tone. The absence of
an effect in the presence of L-NAME indicates that the
functional improvement involves endothelial NO meta-
bolism. The threefold reduction in the EC50 for ACh-
mediated relaxation in the CrP-treated rats is also highly
significant and together with the lack of effect on SNP-
mediated relaxation supports the concept of a direct
beneficial effect on the endothelial cell. There are limi-
ted data indicating direct effects of CrP on endothelium.
Moore and colleagues [42] have shown that CrP, in the
presence of insulin, has a synergistic effect on the recov-
ery rate of intracellular Ca2þ in vascular smooth muscle
cells and can improve Ca2þ-ATPase expression. We
speculate that together with the insulin-sensitizing
effects of chromodulin, CrP may play some part in
improving endothelial Ca2þ flux, in turn improving
vascular tone.
Diabetic Complications and Glomerulosclerosis
The end stages of the metabolic syndrome and type 2
diabetes include pathological complications such asmyo-
cardial ischaemia and glomerulosclerosis, evident in the
JCR:LA-cp model [20,23,26,28]. Urinary albumin is an
indicator of renal microvascular damage, resulting in
increased glomerular permeability and inability to retain
albumin. The damage is evident physically as glomerular
sclerosis and is a major cause of end-stage renal failure in
diabetic patients. Rats fed CLA (with or without CrP) had
significant reduction in urinary albumin concentration.
Consistent with this, but more striking, treatment with
CLA markedly reduced the incidence of glomerulosclero-
sis. We show here, for the first time, that supplementation
with CLA can markedly reduce the severity of glomerular
sclerosis in an animal model of early stage prediabetic
complications. Few studies have addressed the mechan-
isms of kidney damage with respect to lipid deposition
profile and nutritional fatty acid status. However, Ogborn
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et al. [10] concluded that CLA may have anti-inflamma-
tory and antifibrotic effects in the kidney mediated via
prostaglandin E2. Given this and our findings, CLA, alone
or in combination with CrP, has a potential therapeutic
role in the amelioration of renal disease associated with
type 2 diabetes.
In conclusion, the findings of this study offer novel
and striking evidence of the benefit of co-supplementa-
tion of CLA and CrP in the JCR:LA-cp model of insulin
resistance and vascular disease. CLA and CrP, in com-
bination, offer improvements to markers of disease risk,
including lipid profile, hyperinsulinaemia and circulat-
ing adipokines, which are not apparent for either alone.
Moreover, this study provides insight into the potential
of these supplements to reduce macrovascular dysfunc-
tion and protect against glomerular sclerosis and renal
disease, the most important complications of the predia-
betic state. The findings are sufficiently encouraging to
support clinical trial of these promising agents.
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